SCHEMBL5040368

SCHEMBL5040368

NC(=O)c1cnc(N2CCOCC2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.51
ALDH1A1 P00352 5/20 0.49
POLB P06746 3/20 0.47
HRH3 Q9Y5N1 1/20 0.47
PARP1 P09874 1/20 0.47
HPGD P15428 2/20 0.47
PIK3CA P42336 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX15 P16050 1/20 0.46
HTT P42858 2/20 0.45
PIK3CB P42338 1/20 0.44
SIRT6 Q8N6T7 1/20 0.43
AOC3 Q16853 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29889648 1.00 KMO (0.51) KMOALDH1A1POLBHRH3PARP1
SCHEMBL29907656 0.89 KMO (0.60) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL322646 0.89 KMO (0.60) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL17075525 0.87 KMO (0.59) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL27858848 0.87 ALDH1A1 (0.51) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL5041190 0.85 HRH3 (0.50) ALDH1A1HRH3PARP1HPGDKDM4E
SCHEMBL18412787 0.84 ALDH1A1 (0.49) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL29546455 0.83 HRH3 (0.49) ALDH1A1HRH3PARP1HPGDKDM4E
Lithium Ion SCHEMBL17075524 0.83 ALDH1A1 (0.49) KMOALDH1A1POLBHPGDPIK3CA
SCHEMBL5042063 0.81 HDAC3 (0.51) HRH3SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654260-A4 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-09-24 EP claimed
EP-1654260-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 WO claimed
EP-1654260-A4 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-09-24 EP disclosed
EP-1654260-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP disclosed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA KMO 2260/4885ALDH1A1 2820/4885POLB 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.